News >

Maintenance Olaparib Improves PFS in Phase III Ovarian Cancer Trial

Published: Wednesday, Oct 26, 2016

Sean Bohen, MD, PhD

Sean Bohen, MD, PhD

Single-agent olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo in the maintenance setting for patients with advanced BRCA-positive ovarian cancer, according to findings from the phase III SOLO-2 trial announced by AstraZeneca, the manufacturer of the PARP inhibitor.

Although specific data from the trial are not yet available, AstraZeneca reported that the median PFS with olaparib was significantly higher than in the olaparib arm of the phase II Study 19 in a similar population. The safety profile for the PARP inhibitor was consistent with results reported from previous trials.

“We are pleased with the robust improvement in progression-free survival demonstrated by Lynparza in the SOLO-2 trial. We will work with regulatory authorities to make Lynparza tablets available as quickly as possible to patients with ovarian cancer. We remain committed to investigating the full potential of Lynparza, both as monotherapy and in combinations, and to identifying all patients who may benefit from this important medicine,” Sean Bohen, MD, PhD, executive vice president, Global Medicines Development, and Chief Medical Officer at AstraZeneca, said in a statement.

The multicenter phase III SOLO-2 trial included 295 patients with platinum-sensitive, relapsed/recurrent, BRCA-positive ovarian cancer who had received ≥2 prior lines of platinum-based chemotherapy. Patients were randomized to receive either olaparib at 300 mg twice daily or placebo until disease progression.

The latest data from the phase II Study 19, which were presented at the 2016 ASCO Annual Meeting, showed that in patients with platinum-sensitive relapsed serous ovarian cancer, olaparib increased overall survival (OS) when given as maintenance therapy.

Results of the study's extension showed that the PARP inhibitor demonstrated the greatest OS advantage in women who had a BRCA mutation (HR, 0.62), according to lead author Jonathan Ledermann, MD, professor of Medical Oncology at the University College London Cancer Institute and director of the Cancer Research UK & UCL Cancer Trials Centre, who presented the results at the 2016 ASCO Annual Meeting. However, the P values were nominal and did not meet the criterion for statistical significance (P <.0095).

Additional key findings were that both time to first subsequent therapy or death (TFST) and time to second subsequent therapy or death (TSST) were substantially prolonged in patients taking olaparib; again, the greatest benefit was seen in those with a BRCA mutation. Additionally, the unprecedented long-term exposure meant that 13% of all trial patients (15% of BRCA-mutated patients) received maintenance olaparib for at least 5 years. In 3 years of follow-up since the 2012 analysis, there were no new safety findings.

Study 19 assessed patients with platinum-sensitive, recurrent high-grade serous ovarian cancer (n = 265). They had received 2 or more prior regimens of platinum-based chemotherapy and experienced complete response or partial response to their most recent regimen. In a double-blind, 1:1 randomization, half the patients received olaparib 400 mg capsules twice daily as maintenance therapy (n = 136) and half received placebo capsules twice daily (n = 129).

BRCA testing occurred for all patients in the form of case reports that contained the results of previous local germline BRCA testing or retrospective germline BRCA testing or tumor BRCA testing. The division between patients was nearly even between those BRCA mutations (n = 136) and those with wild-type BRCA findings (n = 118), meaning that they either did not have a detected BRCA mutation or they had a BRCA mutation of unknown significance.

The primary endpoint was PFS as measured by RECIST 1.0. Secondary endpoints included OS, safety and tolerability. Exploratory endpoints included TFST and TSST.

In Study 19, the median PFS for patients taking maintenance olaparib was 8.4 months, compared to 4.8 months for the control group (HR, 0.35; P <.0001). The difference in the BRCA mutation subgroup was even more pronounced: 11.2 months with olaparib and 4.3 months with placebo (HR, 0.18; P <.0001).

The third data analysis of Study 19, with data cutoff at September 30, 2015, was performed with data at 77% maturity, OS in the overall study population (n = 265) was a median 29.8 months in the olaparib group and 27.8 months in the placebo group (HR, 0.73; 95% CI, 0.55-0.96; nominal P = .02483). In the BRCA mutation group (n = 136), where the data were at 70% maturity, median OS was 34.9 months for the olaparib group and 30.2 months for placebo (HR, 0.62; 95% CI, 0.41-0.94; nominal P = .02480).

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication